Stevens Capital Closes Out Position in Eli Lilly
Summary
According to a filing with the Securities and Exchange Commission dated Aug. 12, 2025, Stevens Capital Management LP com...
According to a filing with the Securities and Exchange Commission dated Aug. 12, 2025, Stevens Capital Management LP completely exited its position in Eli Lilly and Company (LLY -0.20%), by selling all 12,036 shares in Q2 2025.
Related Articles
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
LLY
Positive3 Dividend Growth Stocks You Can Buy and Forget About
LLY
PositiveLilly sees obesity drug leadership beyond US as it leans on consumer-focused strategy
LLY
Neutral